Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Saranya Sridhar; Alexander R. Luedtke; Edith Langevin; Ming Zhu; Matthew Bonaparte; Tifany Machabert; Stephen J. Savarino; Betzana Zambrano; Annick Moureau; Alena Khromava; Zoe Moodie; Ted Westling; César Mascareñas; Carina Frago; Margarita Cortés; Danaya Chansinghakul; Fernando Noriega; Alain Bouckenooghe; Josh Chen; Su-Peing Ng; Peter B. Gilbert; Sanjay Gurunathan; Carlos A. DiazGranados

doi:10.1056/nejmoa1800820

Abstract

This is the authors' abstract. We don't add key points for this paper.

CYD-TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated persons who had not been exposed to dengue. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530 , NCT01983553 , NCT01373281 , and NCT01374516 .).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sridhar et al. (2018) studied this question.

synapsesocial.com/papers/69dabcac7a67537a8ba3c1f0 https://doi.org/10.1056/nejmoa1800820

View Full Paper

Ask AI

Bookmark

Share

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Abstract

Ask about this paper

Discussion

Cite This Study

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading